NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.55
  • Forecasted Upside: 91.73 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.33
▼ -0.03 (-2.21%)
1 month | 3 months | 12 months
Get New Lexicon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LXRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.55
▲ +91.73% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lexicon Pharmaceuticals in the last 3 months. The average price target is $2.55, with a high forecast of $3.00 and a low forecast of $2.10. The average price target represents a 91.73% upside from the last price of $1.33.
Hold
The current consensus among 6 contributing investment analysts is to hold stock in Lexicon Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/1/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
10/22/2020

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2020JPMorgan Chase & Co.Initiated CoverageUnderweightMedium
i
8/3/2020WedbushReiterated RatingBuy$3.00Low
i
Rating by Liana Moussatos at Wedbush
4/28/2020WedbushReiterated RatingBuy$9.00High
i
Rating by Liana Moussatos at Wedbush
4/28/2020CitigroupLower Price TargetNeutral$2.30 ➝ $2.10High
i
4/27/2020Needham & Company LLCReiterated RatingHoldHigh
i
3/23/2020WedbushReiterated RatingBuy$10.00High
i
Rating by Liana Moussatos at Wedbush
3/15/2020WedbushReiterated RatingBuy$13.00Medium
i
Rating by Liana Moussatos at Wedbush
1/23/2020WedbushReiterated RatingBuy$17.00High
i
Rating by Liana Moussatos at Wedbush
12/22/2019WedbushReiterated RatingBuy$17.00Low
i
Rating by Liana Moussatos at Wedbush
12/11/2019G.ResearchDowngradeBuy ➝ HoldLow
i
Rating by K. Kedra at G.Research, Llc
12/11/2019GabelliDowngradeBuy ➝ HoldLow
i
12/2/2019WedbushReiterated RatingBuy$17.00Medium
i
Rating by Liana Moussatos at Wedbush
11/13/2019WedbushReiterated RatingBuy$17.00Medium
i
Rating by Liana Moussatos at Wedbush
11/8/2019CitigroupDowngradeBuy ➝ Neutral$3.00 ➝ $4.00High
i
10/4/2019WedbushReiterated RatingBuy$17.00Medium
i
Rating by Liana Moussatos at Wedbush
9/11/2019G.ResearchUpgradeHold ➝ BuyN/A
i
Rating by K. Kedra at G.Research, Llc
9/11/2019GabelliUpgradeHold ➝ Buy$3.00High
i
Rating by K. Kedra at Gabelli
8/1/2019WedbushReiterated RatingOutperform$35.00 ➝ $17.00Low
i
Rating by Liana Moussatos at Wedbush
7/30/2019CitigroupLower Price TargetBuy$15.00 ➝ $3.00Low
i
7/29/2019Stifel NicolausDowngradeBuy ➝ Hold$10.00 ➝ $4.00High
i
6/11/2019WedbushSet Price TargetBuy$35.00High
i
Rating by Liana Moussatos at Wedbush
6/3/2019WedbushReiterated RatingBuy$35.00Medium
i
Rating by Liana Moussatos at Wedbush
5/2/2019Needham & Company LLCReiterated RatingHoldLow
i
4/29/2019WedbushReiterated RatingOutperform$34.00 ➝ $35.00High
i
Rating by Liana Moussatos at Wedbush
3/25/2019GabelliUpgradeSell ➝ HoldHigh
i
Rating by K. Kedra at Gabelli
3/25/2019Stifel NicolausLower Price TargetBuy$14.00 ➝ $10.00High
i
3/25/2019Needham & Company LLCReiterated RatingHoldHigh
i
3/13/2019GabelliDowngradeHold ➝ SellHigh
i
Rating by K. Kedra at Gabelli
3/4/2019WedbushBoost Price TargetOutperform$36.00 ➝ $38.00Medium
i
Rating by Liana Moussatos at Wedbush
1/22/2019WedbushSet Price TargetOutperform$42.00 ➝ $36.00High
i
1/22/2019CitigroupReiterated RatingBuy$14.00High
i
11/2/2018GabelliReiterated RatingHoldMedium
i
Rating by K. Kedra at Gabelli
11/2/2018CowenReiterated RatingHoldMedium
i
11/2/2018CitigroupLower Price TargetBuy ➝ Buy$27.00 ➝ $26.00Low
i
7/31/2018Stifel NicolausReiterated RatingBuy ➝ Buy$24.00 ➝ $23.00High
i
7/30/2018Needham & Company LLCReiterated RatingHoldHigh
i
Rating by Alan Carr at Needham & Company LLC
6/25/2018Needham & Company LLCReiterated RatingHoldMedium
i
6/18/2018WedbushReiterated RatingBuy$42.00Low
i
5/22/2018WedbushReiterated RatingOutperform$42.00 ➝ $40.00High
i
5/4/2018CitigroupLower Price TargetBuy ➝ Buy$28.00 ➝ $27.00Medium
i
5/4/2018Stifel NicolausLower Price TargetBuy ➝ Buy$25.00 ➝ $24.00High
i
4/16/2018WedbushBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $40.00Medium
i
2/23/2018Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$15.00 ➝ $10.00High
i
11/30/2017WedbushReiterated RatingOutperform$38.00Medium
i
10/5/2017WedbushReiterated RatingOutperformN/A
i
9/17/2017Needham & Company LLCReiterated RatingBuy$21.00Medium
i
8/7/2017WedbushReiterated RatingOurperform$39.00Low
i
8/1/2017CowenReiterated RatingHoldHigh
i
5/3/2017HC WainwrightSet Price TargetBuy$27.00High
i
Rating by Shaunak Deepak at HC Wainwright
4/5/2017Needham & Company LLCReiterated RatingBuy$21.00Medium
i
3/7/2017CitigroupBoost Price TargetBuy$24.00 ➝ $28.00N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
3/1/2017HC WainwrightReiterated RatingBuy ➝ Buy$26.00 ➝ $27.00N/A
i
Rating by Shaunak Deepak at HC Wainwright
3/1/2017WedbushBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $38.00N/A
i
Rating by Kelechi Chikere at Wedbush
3/1/2017Needham & Company LLCReiterated RatingBuy$21.00N/A
i
2/8/2017WedbushReiterated RatingOutperform$33.00N/A
i
Rating by Kelechi Chikere at Wedbush
1/27/2017Needham & Company LLCReiterated RatingBuyN/A
i
1/5/2017WedbushReiterated RatingOutperform$33.00N/A
i
Rating by Kelechi Chikere at Wedbush
12/25/2016CitigroupSet Price TargetBuy$24.00N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
12/23/2016CowenReiterated RatingMarket PerformN/A
i
12/22/2016WedbushReiterated RatingOutperform$33.00N/A
i
Rating by Kelechi Chikere at Wedbush
12/6/2016WedbushReiterated RatingOutperform$33.00N/A
i
11/2/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Shaunak Deepak at HC Wainwright
10/27/2016WedbushReiterated RatingBuy$33.00N/A
i
10/18/2016HC WainwrightReiterated RatingBuy$26.00N/A
i
Rating by S. Deepak at HC Wainwright
10/7/2016HC WainwrightInitiated CoverageBuy$26.00N/A
i
Rating by S. Deepak at HC Wainwright
9/20/2016WedbushReiterated RatingOutperform$33.00N/A
i
9/12/2016Needham & Company LLCReiterated RatingBuy$21.00N/A
i
Rating by Alan Carr at Needham & Company LLC
9/12/2016CitigroupBoost Price TargetBuy$21.00 ➝ $25.00N/A
i
9/11/2016WedbushReiterated RatingBuy$33.00N/A
i
9/9/2016CowenReiterated RatingHoldN/A
i
Rating by Phil Nadeau at Cowen Inc
8/11/2016Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Alan Carr at Needham & Company LLC
8/5/2016Stifel NicolausBoost Price TargetBuy$25.00 ➝ $26.00N/A
i
8/5/2016WedbushBoost Price TargetOutperform$30.00 ➝ $31.00N/A
i
8/2/2016CitigroupInitiated CoverageBuy$21.00N/A
i
5/31/2016WedbushBoost Price TargetOutperform$28.00 ➝ $30.00N/A
i
5/24/2016WedbushReiterated RatingOutperform$30.00 ➝ $28.00N/A
i
5/6/2016WedbushReiterated RatingOutperform$28.00N/A
i
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$16.00N/A
i
5/4/2016Needham & Company LLCReiterated RatingBuy$21.00N/A
i
Rating by Alan Carr at Needham & Company LLC
5/3/2016CowenReiterated RatingMarket PerformN/A
i
Rating by Phil Nadeau at Cowen Inc
3/2/2016WedbushBoost Price Target$28.00N/A
i
Rating by Liana Moussatos at Wedbush
3/1/2016WedbushReiterated RatingOutperform$26.00 ➝ $28.00N/A
i
Rating by Liana Moussatos at Wedbush
12/2/2015WedbushReiterated RatingOutperform$26.00N/A
i
Rating by Liana Moussatos at Wedbush
11/9/2015WedbushBoost Price TargetOutperform$19.00 ➝ $26.00N/A
i
Rating by Liana Moussatos at Wedbush
11/9/2015Needham & Company LLCReiterated RatingBuy$21.00N/A
i
Rating by Alan Carr at Needham & Company LLC
(Data available from 10/23/2015 forward)
Lexicon Pharmaceuticals logo
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Read More

Today's Range

Now: $1.33
$1.33
$1.38

50 Day Range

MA: $1.53
$1.38
$1.70

52 Week Range

Now: $1.33
$1.34
$5.33

Volume

20,935 shs

Average Volume

1,172,516 shs

Market Capitalization

$142.45 million

P/E Ratio

7.00

Dividend Yield

N/A

Beta

1.38